1. Home
  2. MYN vs LCTX Comparison

MYN vs LCTX Comparison

Compare MYN & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock MuniYield New York Quality Fund Inc.

MYN

Blackrock MuniYield New York Quality Fund Inc.

HOLD

Current Price

$10.01

Market Cap

380.8M

Sector

Finance

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.83

Market Cap

366.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYN
LCTX
Founded
1992
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
380.8M
366.2M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
MYN
LCTX
Price
$10.01
$1.83
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.67
AVG Volume (30 Days)
196.6K
1.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.12%
N/A
EPS Growth
N/A
25.00
EPS
N/A
N/A
Revenue
N/A
$9,499,000.00
Revenue This Year
N/A
$6.32
Revenue Next Year
N/A
$124.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
6.19
52 Week Low
$9.13
$0.37
52 Week High
$10.26
$2.09

Technical Indicators

Market Signals
Indicator
MYN
LCTX
Relative Strength Index (RSI) 43.62 52.70
Support Level $9.90 $1.55
Resistance Level $10.21 $1.84
Average True Range (ATR) 0.07 0.10
MACD -0.01 0.01
Stochastic Oscillator 13.04 58.90

Price Performance

Historical Comparison
MYN
LCTX

About MYN Blackrock MuniYield New York Quality Fund Inc.

Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: